4.5 Article

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease

Journal

NEUROBIOLOGY OF AGING
Volume 33, Issue 1, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2010.06.015

Keywords

Mild cognitive impairment; Alzheimer's disease; Positron emission tomography; (11)C-PIB; (18)F-FDG; Cognition

Funding

  1. Novartis AB
  2. Pfizer
  3. GE Health Care
  4. Johnson Johnson
  5. Swedish Research Council [05817]
  6. (ALF) Stockholm County Council
  7. Karolinska Institutet
  8. Foundation for Old Servants
  9. Gun och Bertil Stohne's Foundation
  10. KI Foundations
  11. Alzheimer Foundation in Sweden
  12. Swedish Brain Foundation
  13. Swedish Brain Power
  14. EC-FP5 [QLK6-CT-2000-00502]
  15. EC-FP6 [QLK6-CT-2000-00502, LSHB-CT-2005-512146]
  16. Novartis Pharmaceuticals Basel
  17. Torreypines Therapeutics
  18. GSK
  19. Wyeth
  20. Bayer

Ask authors/readers for more resources

In this study 5 patients with mild cognitive impairment (MCI) and 9 Alzheimer's disease (AD) patients underwent respectively 3- and 5-year follow-up positron emission tomography (PET) studies with N-methyl [(11)C] 2-(4-methylaminophenyl)-6-hydroxy-benzothiazole ((11)C-PIB) and (18)F-fluorodeoxyglucose ((18)F-FDG) to understand the time courses in AD disease processes. Significant increase in PIB retention as well as decrease in regional cerebral metabolic rate of glucose (rCMRglc) was observed at group level in the MCI patients while no significant change was observed in cognitive function. At group level the AD patients showed unchanged high PIB retention at 5-year follow-up compared with baseline. At the individual level, increased, stable, and decreased PIB retention were observed while disease progression was reflected in significant decrease in rCMRglc and cognition. In conclusion, after a long-term follow-up with PET, we observed an increase in fibrillar amyloid load in MCI patients followed by more stable level in clinical AD patients. The rCMRglc starts to decline in MCI patients and became more pronounced in clinical stage which related to continuous decline in cognition. (C) 2012 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available